UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$438M |
| 2 |
Lockheed Martin
LMT
|
+$402M |
| 3 |
TAL Education Group
TAL
|
+$294M |
| 4 |
Microsoft
MSFT
|
+$269M |
| 5 |
Wells Fargo
WFC
|
+$235M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mastercard
MA
|
+$384M |
| 2 |
Adobe
ADBE
|
+$372M |
| 3 |
Veeva Systems
VEEV
|
+$342M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$289M |
| 5 |
Global Payments
GPN
|
+$287M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.1% |
| 2 | Consumer Discretionary | 13.57% |
| 3 | Healthcare | 12.46% |
| 4 | Financials | 11.55% |
| 5 | Communication Services | 9.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1876
Invesco Mortgage Capital
IVR
$795M
| $1.12M | ﹤0.01% |
33,257
+1,817
| +6% | +$56.3K |
|
1877
Quanex
NX
$967M
| $1.12M | ﹤0.01% |
50,560
-562
| -1% | -$11.6K |
|
|
KAMN
1878
DELISTED
Kaman Corp
KAMN
| $1.12M | ﹤0.01% |
19,593
| – | – |
|
1879
Carpenter Technology
CRS
$27.8B
| $1.12M | ﹤0.01% |
38,304
+3,049
| +9% | +$70.6K |
|
1880
Innoviva
INVA
$1.49B
| $1.12M | ﹤0.01% |
90,022
| – | – |
|
|
SCS
1881
DELISTED
Steelcase
SCS
| $1.12M | ﹤0.01% |
82,306
| – | – |
|
1882
Progyny
PGNY
$2.18B
| $1.11M | ﹤0.01% |
26,299
+15,699
| +148% | +$511K |
|
1883
Benchmark Electronics
BHE
$2.92B
| $1.11M | ﹤0.01% |
41,271
| – | – |
|
|
SASR
1884
DELISTED
Sandy Spring Bancorp Inc
SASR
| $1.11M | ﹤0.01% |
34,626
| – | – |
|
1885
Cytokinetics
CYTK
$10.5B
| $1.11M | ﹤0.01% |
53,575
+647
| +1% | +$11.8K |
|
1886
Radware
RDWR
$1.2B
| $1.11M | ﹤0.01% |
39,918
-3,500
| -8% | -$87.4K |
|
1887
Fulgent Genetics
FLGT
$524M
| $1.1M | ﹤0.01% |
+21,200
| New | +$886K |
|
|
GNMK
1888
DELISTED
GenMark Diagnostics, Inc
GNMK
| $1.1M | ﹤0.01% |
75,522
-4,048
| -5% | -$53.7K |
|
1889
Standard Motor Products
SMP
$885M
| $1.1M | ﹤0.01% |
27,236
+6,178
| +29% | +$290K |
|
|
MYOV
1890
DELISTED
Myovant Sciences Ltd.
MYOV
| $1.1M | ﹤0.01% |
39,793
+4,447
| +13% | +$86.6K |
|
|
AMWD
1891
DELISTED
American Woodmark
AMWD
| $1.09M | ﹤0.01% |
11,663
+1,353
| +13% | +$123K |
|
|
ENLC
1892
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
| $1.09M | ﹤0.01% |
294,234
+10,067
| +4% | +$33K |
|
1893
Theravance Biopharma
TBPH
$876M
| $1.08M | ﹤0.01% |
60,794
+17,366
| +40% | +$312K |
|
1894
BellRing Brands
BRBR
$1.32B
| $1.08M | ﹤0.01% |
44,435
-2,200
| -5% | -$47.9K |
|
1895
Eagle Bancorp
EGBN
$843M
| $1.08M | ﹤0.01% |
26,149
| – | – |
|
1896
GoPro
GPRO
$121M
| $1.08M | ﹤0.01% |
130,325
-8,019
| -6% | -$57.8K |
|
1897
Madrigal Pharmaceuticals
MDGL
$11.9B
| $1.08M | ﹤0.01% |
9,701
+317
| +3% | +$38.7K |
|
1898
Vanguard Morningstar Mega Cap ETF
MGC
$10.4B
| $1.08M | ﹤0.01% |
+8,070
| New | +$1.02M |
|
1899
Supernus Pharmaceuticals
SUPN
$2.74B
| $1.07M | ﹤0.01% |
42,630
| – | – |
|
|
FOE
1900
DELISTED
Ferro Corporation
FOE
| $1.07M | ﹤0.01% |
73,259
| – | – |
|
Similar funds
UBS AM's Q4 2020 Portfolio in Review
As of Q4 2020, UBS AM held 2,632 positions worth $213B, up 15% from $186B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
UBS AM's Q4 2020 filing shows 139 new, 1,393 increased, 625 reduced and 83 closed positions. Its largest new stake was Maravai LifeSciences: 3,763,012 shares worth $106M. The largest sale was Mastercard, an estimated $384M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- UBS AM's largest Q4 2020 buy was Maravai LifeSciences: 3,763,012 shares worth $106M.
- UBS AM added most to Apple in Q4 2020, an estimated $438M increase.
- UBS AM's biggest Q4 2020 reduction was Mastercard, cutting an estimated $384M.
- UBS AM fully exited State Street Technology Select Sector SPDR ETF in Q4 2020, selling an estimated $115M.
- UBS AM's ten largest holdings make up 23% of its $213B portfolio in Q4 2020.
- UBS AM opened 139 new positions and closed 83 in Q4 2020.
- UBS AM's portfolio value rose 15% quarter-over-quarter to $213B.
Based on UBS AM's 13F filing for Q4 2020, filed 17 Feb 2021.